MannKind Corporation (Nasdaq: MNKD) today released new
information related to the market potential for AFRESA, MannKind’s ultra
rapid-acting insulin.
In a market survey conducted in May 2009 involving 101 endocrinologists
and 102 primary care physicians (all based in the United States) and
utilizing MannKind’s next generation inhaler, physicians expressed a
preference for AFRESA for approximately 25% of both type 1 and type 2
patients that would qualify for use of AFRESA. Endocrinologists surveyed
indicated a higher preference share for their type 2 patients
(approximately 26%) than their type 1 patients (approximately 19%).
Primary care physicians surveyed indicated a nearly equal preference
share for their type 1 patients (approximately 26%) and type 2 patients
(approximately 25%).
Alfred Mann, Chairman and Chief Executive Officer of MannKind,
commented, “We are pleased with this latest survey conducted by a
leading market research firm. While preference share does not translate
directly into market share, this latest survey helps us to gauge
physician intent in prescribing AFRESA in their clinical practices.”
Dr. Peter Richardson, Corporate Vice President and Chief Scientific
Officer, commented, “We believe that these results are a strong show of
support for our next generation inhaler, which is not only smaller and
easier to use, but also requires lower airflow, provides better
cartridge emptying with one inhalation and requires less powder to
deliver the same plasma insulin.”
About AFRESA®
AFRESA is an ultra rapid-acting insulin product that has completed Phase
3 trials. The pharmacokinetic profile of AFRESA sets it apart from all
other insulin products. The large surface area of the lung provides
unique access to the circulatory system. The pH-sensitive AFRESA
particles immediately dissolve upon contact with the lung surface,
releasing insulin monomers that rapidly enter the bloodstream. It
achieves peak insulin levels within 12-14 minutes of administration,
effectively mimicking the release of meal-time insulin observed in
healthy individuals, but which is absent from patients with diabetes.
AFRESA is also the trade name for the product that MannKind has proposed
to the FDA.
About MannKind Corporation
MannKind Corporation (Nasdaq: MNKD) focuses on the discovery,
development and commercialization of therapeutic products for patients
with diseases such as diabetes and cancer. Its diabetes pipeline
includes AFRESA® and MKC253.
